Chimeric G protein based rabies vaccine
US7901691B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Aug 12, 2005 |
| Grant date | Mar 8, 2011 |
| Priority date | — |
| Expiry date | Mar 9, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/20134
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel chimeric protein of rabies virus designed to express a chimeric G protein at a high level in transgenic plants. A gene was also designed and chemically synthesised to encode the chimeric G protein and expressed at high level in plant tissue. The gene was expressed in transgenic tobacco plants to examine its therapeutic efficacy against infection by rabies virus. The chimeric G protein was enriched in plant membranes. The BalbC mice were immunised with the plant leaf expressed G-protein. Plant derived chimeric G protein elicited higher immune response as compared to the commercial vaccine. The mice displayed protective immunity when they were challenged with live virus. Chimeric G protein expressed at high level in plant leaves was demonstrated to function as a commercially valuable subunit vaccine against rabies virus infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.